tailieunhanh - Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis

The two 52-week INPULSIS trials investigated nintedanib versus placebo in patients with IPF, FVC ≥50% predicted and DLco 30–79% predicted. The 24-week INSTAGE trial investigated nintedanib plus sildenafil versus nintedanib alone in patients with IPF and DLco ≤35% predicted. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN